Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC

Inclusion Criteria:

* Give written informed consent prior to study, with understanding that the patient has the right to withdraw from the study at any time without prejudice
* Be female and ≥18 and ≤75 years of age
* Be ambulatory and have ECOG performance stastus of ≤1
* Have histological confirmed breast cancer,and the speciman confirmed ER negative,PR negatiev, and HER-2 negative by immunochemistry technich of Fudan cancer hospital.
* Locally advanced or metastastic breast cancer who didn't receive first-line chemotherapy. No matter whether the patient has received anthracyclin or taxane treatment as neo-adjuvant or adjuvant treatment.
* Have at least one target lesion according to the RECIST criteria.

Exclusion criteria:

* Preganant or lactating women
* Advaced patient has received one or more chemotherapies
* Chemotherapy within four weeks preceding treatment start
* ECOG ≥ 2
* Radiotherapy to the axial skeleton within the 4 weeks preceding study treatment start or insufficient recovery from the effects of prior radiotherapy
* Participation in any investigational drug study within 4 weeks preceeding treatment start
* Evidence of CNS metastasis
* History of another malignacy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast cancer
* Abnormal laboratory values: hemoglobin \< 8. 0g/dl, neutrophil\< 1.5×109/L, platelet\< 100×109/L.
* serum creatine \> upper limit of normal (ULN)
* serum bilirubin \> ULN
* ALT and AST \>5×ULN
* AKP \>5×ULN
* Serious uncontrolled intercurrence infection
* Life expectancy of less than 3 months